BNP PARIBAS EXANE Upgrades Siemens Healthineers AG - Depositary Receipt () (SMMNY)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 11 2024
0mins
Should l Buy ?
Source: NASDAQ.COM
Analyst Upgrade: BNP PARIBAS EXANE has upgraded Siemens Healthineers AG's outlook from Neutral to Outperform, with a projected one-year price target of $32.74/share, indicating an 11.02% upside from its current price of $29.49/share.
Institutional Investment Increase: There has been a significant increase in institutional ownership of Siemens Healthineers AG, with a 44.44% rise in the number of funds reporting positions and a 70.59% increase in total shares owned over the last three months.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
